Get the Stockscreener App
1.13
0.00%
0.00
After Hours:
1.13
Citius Oncology Inc stock is traded at $1.13, with a volume of 161.69K.
It is up +0.00% in the last 24 hours and down -15.67% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.13
Open:
$1.12
24h Volume:
161.69K
Relative Volume:
0.45
Market Cap:
$95.82M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.90%
1M Performance:
-15.67%
6M Performance:
-23.13%
1Y Performance:
+5.61%
1-Day Range:
$1.10
$1.1797
1-Week Range:
$0.9384
$1.20
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.13 | 95.82M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Raises $18M Through Direct Offering - TipRanks
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Benzinga
Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada
Citius Oncology added to the Russell Microcap Index - MSN
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology raises $18 million to support cancer therapy launch - Investing.com
Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com UK
Citius Oncology stock tumbles after $18M capital raise - Investing.com
Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire
Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com
What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in
Is Citius Oncology Inc a good long term investmentLow Beta Stocks & Free Rapid Profit Acceleration - earlytimes.in
Citius Oncology Launches Lymphir In US For Skin Cancer - MSN
Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria
Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com
Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com
Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com
Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga
Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks
Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView
Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com
Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa
Citius Oncology stock soars after commercial launch of LYMPHIR therapy - Investing.com
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - Seeking Alpha
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a - GuruFocus
Citius Oncology Launches Cancer Drug Lymphir in the US - marketscreener.com
Citius Oncology launches lymphir for cutaneous T-cell lymphoma By Investing.com - Investing.com South Africa
Citius Oncology launches lymphir for cutaneous T-cell lymphoma - Investing.com
Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside - Stocktwits
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) – Company Announcement - Financial Times
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):